Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGNX Stock Forecast 2025-2026
$1.37
Current Price
$86.66M
Market Cap
Buy 2
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to MGNX Price Targets
+265.0%
To High Target of $5.00
+119.0%
To Median Target of $3.00
+46.0%
To Low Target of $2.00
MGNX Price Momentum
-10.5%
1 Week Change
0.0%
1 Month Change
-60.9%
1 Year Change
-57.8%
Year-to-Date Change
-62.4%
From 52W High of $3.64
+38.4%
From 52W Low of $0.99
📊 TOP ANALYST CALLS
Did MGNX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MacroGenics is one of their latest high-conviction picks.
Latest MGNX Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, MGNX has a neutral consensus with a median price target of $3.00 (ranging from $2.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.37, the median forecast implies a 119.0% upside. This outlook is supported by 2 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 46.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGNX Analyst Ratings
2
Buy
5
Hold
0
Sell
MGNX Price Target Range
Low
$2.00
Average
$3.00
High
$5.00
Current: $1.37
Latest MGNX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGNX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $2.00 |
| Sep 17, 2025 | Barclays | Etzer Darout | Overweight | Assumes | $3.00 |
| Aug 15, 2025 | Leerink Partners | Outperform | Maintains | $5.00 | |
| May 20, 2025 | B. Riley Securities | Mayank Mamtani | Neutral | Maintains | $3.00 |
| May 14, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $3.00 |
| May 14, 2025 | Stifel | Stephen Willey | Hold | Maintains | $5.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Maintains | $2.00 |
| Nov 7, 2024 | JMP Securities | Silvan Tuerkcan | Market Perform | Downgrade | $N/A |
| Nov 6, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Sep 18, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Aug 15, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $14.00 |
| Aug 7, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $5.00 |
| Aug 1, 2024 | BTIG | Kaveri Pohlman | Neutral | Downgrade | $N/A |
| Aug 1, 2024 | HC Wainwright & Co. | Robert Burns | Neutral | Reiterates | $4.00 |
| Jul 31, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $8.00 |
| Jul 31, 2024 | Guggenheim | Kelsey Goodwin | Neutral | Downgrade | $N/A |
| Jul 31, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Maintains | $8.00 |
| Jul 31, 2024 | B. Riley Securities | Mayank Mamtani | Neutral | Downgrade | $5.00 |
| Jul 29, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $9.00 |
Macrogenics Inc. (MGNX) Competitors
The following stocks are similar to MacroGenics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Macrogenics Inc. (MGNX) Financial Data
Macrogenics Inc. has a market capitalization of $86.66M with a P/E ratio of 25.3x. The company generates $127.63M in trailing twelve-month revenue with a -59.5% profit margin.
Revenue growth is -34.2% quarter-over-quarter, while maintaining an operating margin of +25.6% and return on equity of -81.1%.
Valuation Metrics
Market Cap
$86.66M
Enterprise Value
$-22,723,812
P/E Ratio
25.3x
PEG Ratio
-0.4x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-34.2%
Gross Margin
+84.1%
Operating Margin
+25.6%
Net Margin
-59.5%
EPS Growth
-70.1%
Financial Health
Cash/Price Ratio
+168.9%
Current Ratio
5.2x
Debt/Equity
55.2x
ROE
-81.1%
ROA
-26.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Macrogenics Inc. (MGNX) Business Model
About Macrogenics Inc.
What They Do
Develops innovative protein-based cancer therapeutics.
Business Model
Macrogenics generates revenue through the discovery and development of monoclonal antibodies and bispecific molecules for cancer treatment. Its business model is centered on partnerships with other pharmaceutical companies, which helps in advancing its research pipeline and bringing novel therapies to market.
Additional Information
Founded in 2000 and based in the United States, Macrogenics utilizes proprietary technology platforms like the DART platform to create multispecific antibodies. The company's focus on precision and targeted therapies positions it as a key player in the biopharmaceutical industry, particularly in oncology and personalized medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
341
CEO
Mr. Eric Blasius Risser
Country
United States
IPO Year
2013
Website
www.macrogenics.comMacrogenics Inc. (MGNX) Latest News & Analysis
Latest News
Quick Summary
MacroGenics' CEO Eric Risser will speak at the Evercore Healthcare Conference on December 4, 2025. A webcast will be available on the company's investor relations website.
Why It Matters
Eric Risser's participation in the Evercore Healthcare Conference may highlight MacroGenics' strategic direction and innovations, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
25 days ago
Quick Summary
MacroGenics, Inc. (NASDAQ: MGNX) reported its Q3 2025 financial results and shared updates on corporate developments. Further details can be expected in the full report.
Why It Matters
MacroGenics' Q3 financial results and corporate updates can indicate its growth potential and market performance, influencing investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MacroGenics (MGNX) reported Q3 earnings of $0.27 per share, surpassing the Zacks estimate of a loss of $0.48. This is a decline from $0.90 per share in the same quarter last year.
Why It Matters
MacroGenics' earnings beat expectations, signaling improved performance and potential market confidence. However, the decline from last year's earnings may raise concerns about future growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
MacroGenics (MGNX) has formed a hammer chart pattern, suggesting support after recent losses. This, along with rising earnings estimate revisions, may indicate a potential trend reversal.
Why It Matters
The hammer chart pattern suggests potential price support for MacroGenics (MGNX), while rising earnings estimates may signal a bullish trend reversal, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
MacroGenics, Inc. (Nasdaq: MGNX) CEO Eric Risser will participate in a fireside chat at the Stifel 2025 Healthcare Conference on November 13, 2025, at 4:00 pm ET in New York.
Why It Matters
MacroGenics' CEO's participation in a major healthcare conference highlights potential developments and investor interest, influencing stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MacroGenics, Inc. (Nasdaq: MGNX) will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:30am ET.
Why It Matters
MacroGenics’ CEO presenting at a major investment conference signals potential growth opportunities and increased visibility, which may attract investor interest and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MGNX Stock
What is Macrogenics Inc.'s (MGNX) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Macrogenics Inc. (MGNX) has a median price target of $3.00. The highest price target is $5.00 and the lowest is $2.00.
Is MGNX stock a good investment in 2026?
According to current analyst ratings, MGNX has 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGNX stock?
Wall Street analysts predict MGNX stock could reach $3.00 in the next 12 months. This represents a 119.0% increase from the current price of $1.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Macrogenics Inc.'s business model?
Macrogenics generates revenue through the discovery and development of monoclonal antibodies and bispecific molecules for cancer treatment. Its business model is centered on partnerships with other pharmaceutical companies, which helps in advancing its research pipeline and bringing novel therapies to market.
What is the highest forecasted price for MGNX Macrogenics Inc.?
Price targets from Wall Street analysts for MGNX are not currently available. The stock is trading at $1.37.
What is the lowest forecasted price for MGNX Macrogenics Inc.?
The lowest price target for MGNX is $2.00 from Robert Burns at HC Wainwright & Co., which represents a 46.0% increase from the current price of $1.37.
What is the overall MGNX consensus from analysts for Macrogenics Inc.?
The overall analyst consensus for MGNX is neutral. Out of 16 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are MGNX stock price projections?
Stock price projections, including those for Macrogenics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 6:03 PM UTC